Eli Lily's CEO David Ricks announced a new US factory worth over $6 Billion as per several reports that will manufacture the awaited weight loss pill: Orforglipron. The company had earlier announced that the weight loss pill had successfully met the “primary and all key secondary endpoints” in a large clinical trial, paving the way for global regulatory submissions.

“With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting,” said Kenneth Custer, Eli Lilly’s executive vice president and president of cardiometabolic health.

“If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated around the world.”

This comes after President Donald Trump on its website TrumpRx allowed Americans to purchase prescription medication from pharmaceutical companies at discounted rates, among them also include GLP-1 medications. The Trump administration also unveiled agreements with Eli Lily to make these drugs more affordable. Trump has taken a special interest in the 'fat drug'.

In an exclusive interview with CNN's Erin Burnett, CEO Ricks shared that this new weight loss pill will be coming out next year. Eli Lily is also the company that has made Zepbound. Talking about the side effects of weight loss drugs, which included weight loss drugs reducing age, or people reporting pancreas problems, or the drugs changing brain's make up to curb down cravings, the CEO said that these were just a selected few people reporting such results. He said that he has received emails, photos from before and after of people who have been on weight loss drugs and how they are with their transition. "There were people who were changing not just the way they look, but also their health status in this country and around the world. So most of the evidence is from the opposite side," he said.

In terms of life expectancy, he said that "most of the data that we have collected it [weight loss drugs] extends life". How? "They do it through preventing diabetes, preventing heart attacks, and preventing other serious anomalies that comes through obesity," said the CEO.

What Is Orforglipron?

Originally discovered by Japan’s Chugai Pharmaceutical and later licensed to Eli Lilly in 2018, orforglipron is now in Phase 3 trials. The company is testing it not just for weight management and type 2 diabetes but also for conditions linked to obesity, including obstructive sleep apnea and hypertension.

Why An Oral Option Matters

Injectable GLP-1 receptor agonists like semaglutide and tirzepatide have already transformed obesity and diabetes care, but accessibility remains a hurdle. For many patients, injections are intimidating, inconvenient, or simply not practical in daily life.

That’s where an oral pill could be a game-changer. A once-daily tablet could remove psychological and logistical barriers, making it easier for patients to stay on treatment. And given the rising global burden of obesity, which significantly raises the risk of cardiovascular disease, stroke, and some cancers, the demand for more convenient treatment options has never been greater.

Pills vs. Injections: Which Works Better?

The big question now is whether oral GLP-1 drugs are as effective as their injectable counterparts.

A 2021 research review published in Springer Nature, offers some clues. After examining multiple studies, researchers concluded that oral semaglutide, a similar class of drug, provided “similar or better efficacy and similar tolerability” compared to injectable GLP-1 receptor agonists.

Also Read: How To Identify A Counterfeit Ozempic? Look For These Signs

In some cases, oral versions were found to be just as effective for weight loss and lowering A1C levels in people with type 2 diabetes. However, the review focused on patients already using insulin, which may have influenced outcomes. Experts emphasize that while results are encouraging, more research is still needed to directly compare oral and injectable versions in broader populations.

A health minister is standing down at the age of 53 from her role in government after she was diagnosed with incurable breast cancer. Ashley Dalton, has been diagnosed with incurable metastatic breast cancer and wants to continue her role as the MP for West Lancashire because her work is "central" to her identity. However, she would stand down from her role as a health minister because she is concerned that she will become too sick to fulfil "any of the roles I love" if she is to continue to serve the designation.

Also Read: 3 US Hospitals Rank in the Top 10 List of World's Best Hospitals

Writing in The Times, she said, "I have to consider what reasonable adjustments I might make. Before being made a government minister, I was elected by the people of West Lancashire to represent them as their MP. My priority has to be to do that job. But to continue to serve my constituents as they deserve, whilst adequately managing the side effects of chemo as well as caring for my elderly mum, I must make reasonable adjustments to my workload. The alternative would likely be more regular trips to Liverpool Aintree, making myself sick and unable to fulfil any of the roles I love.”

Ashley Dalton Health Update

She writes that she is currently undergoing chemotherapy treatment. She also writes that cancer is different for every patient and that this is not a "homogenous disease".

She also writes that while anyone who hears of chemotherapy thinks of the absolute worse, with IV drip hanging in their arm, in hospital and bald. However, she clarifies that this is not the case with her. "But, for now at least, my treatment is not like that. You likely wouldn’t be able to guess I am undergoing major medical intervention as I stand in front of you. I take five tablets twice a day for two weeks, with a week of rest as part of a three-week cycle," she writes.

Also Read: Giant 99th Percentile Baby Of 5.9Kg Born In New York Has Taken The Internet By Storm

She also says that her disease is stable and she is also well aware that she will never beat the cancer. When people ask her when will she know that she has beaten her cancer, she says, "when I have died of something else."

When Dalton was diagnosed with metastatic — stage 4 — breast cancer, she was told, gently but firmly, that support was available. That she could step back. That she could give up work.

“But the biggest mistake anyone could make about me and my cancer is to write me off,” she has said.

For some, stepping away from work is the right and necessary choice. “But just as cancer is not homogeneous,” Dalton writes, “neither are we people living with cancer.” Her diagnosis did not mark the end of her public life. Instead, it sharpened her sense of purpose — particularly in shaping how government responds to serious illness.

A Cancer Patient At The Head Of The Cancer Plan

As a health minister in the UK government, Dalton led the development of the National Cancer Plan — a sweeping strategy aimed not only at improving survival rates but transforming life after diagnosis.

Beyond what she describes as “the fastest rate of improvement in health outcomes for cancer patients in a century,” the plan is designed to save 320,000 lives over its course. But the statistic she seems most proud of is less numerical and more human.

“What I’m so proud of is the support the plan gives to people living with cancer not just to survive, but to live, and to live well. To work, to have a family, to thrive. To exist beyond the diagnosis.”

It is policy shaped by lived experience. Dalton has insisted that cancer patients remain central to decision-making — “because there was a cancer patient at the head of the plan.”

The National Cancer Plan places stronger emphasis on early diagnosis, faster treatment pathways, and equitable access to care. But it also pushes for something often overlooked: reasonable adjustments in workplaces, better psychosocial support, and a recognition that patients are not defined solely by their illness.

Beyond Cancer: A Broader Health Agenda

In just 12 months, Dalton led work on three major national strategies:

• The HIV Action Plan
• The Men’s Health Strategy
• The National Cancer Plan

“These aren’t just words on paper,” she wrote. “They will make real and positive differences to the lives of people in our communities.”

The HIV Action Plan builds on efforts to reduce new transmissions and tackle stigma, while improving access to testing and treatment. The Men’s Health Strategy addresses disparities in life expectancy, mental health support, and late diagnosis of conditions like prostate cancer. Together, they reflect a broader push toward preventive, inclusive healthcare.

Dalton’s approach has consistently centred lived realities — from men reluctant to seek help, to people navigating long-term treatment, to families balancing work and care.

World Cancer Day; And A Personal Reckoning

Launching the Cancer Plan on World Cancer Day was a professional milestone. It was also deeply personal.

“Advocating for reasonable adjustments to allow cancer patients to thrive meant that to continue thriving myself, I have to consider what reasonable adjustments I might make.”

Before becoming a minister, Dalton was elected to represent West Lancashire as a Member of Parliament. That responsibility, she says, remains her priority. But chemotherapy side effects and caring for her elderly mother forced her to confront limits.

“The alternative would likely be more regular trips to Liverpool Aintree, making myself sick and unable to fulfil any of the roles I love.”

In a difficult decision, she chose to step down from her ministerial role and return to the back benches — not as a retreat, but as a recalibration.

“For that reason, I have taken the difficult — but I think correct — decision to return to the back benches.”

Service, Redefined

Dalton is clear: she is not leaving politics. She is not relinquishing her voice.

“I’m not stepping away from public life, the government, or my work as a politician,” she has said. “I’m taking the steps necessary to continue to represent the people of West Lancashire… and I will continue to use my voice to fight for the rights of cancer patients to live as well as they are able for as long as possible.”

A list by Newsweek features World's Best Hospital list in 2026. The list analyzed hospitals across 32 countries, including Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, France, Germany, India, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, Norway, the Philippines, Saudi Arabia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, the United Arab Emirates, the United Kingdom and the United States of America.

Also Read: Ashley Dalton Diagnosed With Incurable Breast Cancer Stands Down From Her Position

These countries were also selected using multiple comparability criteria, which also included:

• Population size
• Life expectancy
• Standard of living
• Hospital density
• Availability of reliable data

Out of the 250 hospitals listed by Newsweek, using data from Statista, the hospitals in the United States hold four ranks in the top 10 list.

How Have The Hospitals Been Reviewed?

Each hospital was assessed and scored using four key data sources: recommendations from medical professionals—including doctors, hospital administrators and other healthcare experts—hospital quality metrics, existing patient experience data, and Statista’s Patient-Reported Outcome Measures (PROMs) Implementation Survey. PROMs are standardized, validated questionnaires completed by patients to evaluate their own functional well-being and overall quality of life.

The 2026 methodology builds on previous editions of the ranking, with Philippines and Turkey included for the first time. This year’s evaluation places greater emphasis on hospital quality metrics, integrates newly available accreditation, safety, quality and patient experience data from multiple countries, and further strengthens the importance of PROMs through increased weighting and an updated Implementation Survey.

More than 2,500 hospitals were evaluated globally, with special distinction awarded to the top 250 institutions. The five highest-ranked hospitals are: Mayo Clinic-Rochester (Rochester, Minnesota); Toronto General-University Health Network (Toronto); Cleveland Clinic (Cleveland); Karolinska Universitetssjukhuset (Stockholm); and Massachusetts General Hospital (Boston).

Access to reliable and transparent data can play a crucial role in guiding healthcare decisions. This ranking aims to serve as a practical reference for patients, families and healthcare leaders seeking trusted insight into some of the world’s most respected medical institutions.

Where Do Indian Hospitals Rank In The List?

Of the 250 list of hospitals, India made it to the list with four hospitals. Medanta - The Medicity ranked at 110, All India Institute of Medical Sciences - Delhi ranked at 115, PGIMER - Postgraduate Institute of Medical Education and Research ranked at 214 and CMC Vellore - Town Campus at 245.

Just ahead of Holi, the Food Safety and Standards Authority of India (FSSAI) seized fake paneer near Noida, along with 1,400 kg of fake khoya in Jhansi, and 400kg of expired ghee. The FSSAI started a series of raids in the Indian state of Uttar Pradesh and Rajasthan ahead of the festivities, when the demands of these food items are increased. Health and Me previously reported on the FSSAI raids in Kanpur where oil, rotten dates, and sweets were found to be adulterated.

Paneer Seized Near Noida At Yamuna Express Way

FSSAI on 27 February posted a video where officials could be seen disposing of a large quantity of adulterated paneer at a landfill site. FSSAI noted that the consignment was intercepted late at night at Jewar Toll Plaza on the Yamuna Expressway. The sample was seized and sent for laboratory testing, while rest of the stock was destroyed immediately.

From time and again news of adulterated paneer have made headline. Fake paneer is an adulterated, non-dairy, or low-quality substitute made using starch, hydrogenated oil (vanaspati), urea, detergent, or ammonium sulphate to mimic real milk cheese. It is found in street foods and local markets, and feels rubbery.

How to test fake paneer? The easy way to test is to use iodine on it, and if it turns blue or black, it means it is fake.

Read: Kanpur Food Adulteration: FSSAI Seizes 14,000L of Oil, 1320Kg Rotten Dates And More Ahead Of Festive Season

1,400 kg Of Adulterated Khoya In Jhansi

In another series of raid by FSSAI in Jhansi, officials confiscated nearly 1,400kg of adulterated khoya. This too happened as a part of a late night operation.

A mobile laboratory unit detected starch adulteration and fungal contamination in the product. The khoya confiscated was worth 3.5 lakh and was destroyed on the spot after inspectors determined that they were unsafe for consumption.

In the images shared by FSSAI, it could be clearly seen that mould-infested khoya had been dumped and discarded.

Expired Food Seized In Rajasthan

FSSAI on March 1 raided in Salumbar district of the Indian state of Rajasthan, where authorities confiscated nearly 400 kg of expired and contaminated food items. This included ghee, cooking oil, tea leaves and spices. Samples from several shops were collected and sent for tests.

Cases Of Contaminated Food In India

Not too long ago, Health and Me reported food contamination from Indore's Bhagirathpura, the same place which was the epicentre of water contamination that took many lives. Health and me also reported the news of Horlicks adulteration in Odisha.

In another news, bacteria were found in Amul milk packages, along with Mother Dairy and Country Delight. Eggoz too landed in a controversy, when a YouTube video went viral claiming that the sample tested positive for Nitrofuran.

MicrobioTx, a Bengaluru-based gut health startup tested samples from urban populations across 9 Indian states and 14 cities and found that people are significantly exposed to pesticides, insecticides, antibiotics, steroidal growth regulators, and forever chemicals.

The independent study found:

• 78% were exposed to pesticide residues, with 36% exposed to three or more pesticides, indicating cumulative exposure that may pose serious health risks.
• 54% showed presence of antibiotics, linked to antimicrobial resistance, harder-to-treat infections, and disruption of the gut microbiome that may contribute to metabolic disorders.
• 39% were exposed to steroids, compounds that may cause endocrine disruption and increased carcinogenic risk.
• 38% tested positive for forever chemicals, persistent toxins that may cause cancer risk, reduced fertility, thyroid disease, hormone suppression, high cholesterol, liver damage, and ulcerative colitis.
• 17% of the samples had 10 or more toxins in their blood across 3 categories, indicating hidden chronic exposure.